Revolutionizing Medicine: The Unstoppable Alliance Changing mRNA Therapeutics Forever
Wacker Biotech and RNAV8 Bio have joined forces to revolutionize mRNA engineering, transforming treatments for genetic and common diseases. Wacker Biotech specializes in producing high-quality mRNA and formulating lipid nanoparticles…
This Groundbreaking Partnership Might Change the Game for mRNA Therapeutics
Wacker Biotech and RNAV8 Bio have formed a strategic partnership to advance mRNA therapeutics. Wacker Biotech brings its expertise in microbial fermentation, processing up to 650 liters of material, to…
The Fall of a Biotech Titan: What Happened to AmplifyBio?
AmplifyBio, a promising biotech company based in central Ohio, has closed its operations, despite its ambitious beginnings and significant investments. Founded in 2021 as a gene therapy offshoot from Battelle,…
Unlocking the Next Frontier in Medicine: How a New Alliance Promises to Transform mRNA Therapeutics
Wacker Biotech and RNAV8 Bio have partnered to advance mRNA therapeutics, aiming to revolutionize treatment landscapes for various diseases. Wacker Biotech specializes in microbial fermentation, producing high-quality pharmaceutical proteins and…
Biotech’s Bold Gamble: Can Relay Therapeutics Thrive After Radical Overhaul?
Relay Therapeutics is undergoing significant restructuring, including three layoff rounds within a year, to tackle economic challenges and refocus on key clinical goals. The company has slashed its research budget…
The Unseen Battle Behind Relay Therapeutics’ Bold Restructuring
Relay Therapeutics is undergoing significant changes with workforce reductions and cost-cutting to focus on clinical ambitions. The company has reduced its annual research budget by 75% and cut 70 jobs…
The Bold Reawakening of a Biotech Maverick: F-star’s Independence Journey
F-star Therapeutics has transitioned to an independent entity, reclaiming its narrative after separating from former acquirer invoX Pharma. The U.K.-based company is focused on advancing its innovative bispecific antibody platform,…
Why F-star Therapeutics’ Independence Could Spark a New Wave in Biotech Innovation
F-star Therapeutics is emerging as an independent biotech company following its $161 million acquisition by invoX Pharma, a subsidiary of Sino Biopharmaceutical. The acquisition faced regulatory challenges, particularly with the…
The Explosive Race to Lead in Pharmaceutical R&D: Who’s Investing Big in 2024?
The pharmaceutical industry's R&D is driven by a competitive pursuit of innovation and breakthroughs. Merck continues its prominence in oncology and vaccines, aiming for long-term impact through strategic R&D investment.…
The Hidden Force Revolutionizing Medicine—And It’s Not AI
Abzena is at the forefront of innovation in bioconjugation and complex biologics, transforming drug development. Led by Dave Williamson, a former soldier turned Chief Information Officer, the company leverages big…